Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626392 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 277
- Enrollment target
NCT00626392 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 277 participants.
The verdict
NCT00626392, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 277 participants
- Enrollment target
Study Summary
The primary purpose of this study was to assess the effect of aspirin (ASA) on niacin extended-release (NER)-induced flushing in subjects with dyslipidemia.
Interventions
- DRUG aspirin (ASA)
- DRUG niacin extended-release (NER)
- DRUG aspirin placebo (ASA Pbo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626392
The ClinicalTrials.gov registry entry for NCT00626392 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which aspirin (ASA) is the first listed.
NCT00626392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00626392 about?
NCT00626392 is a clinical study titled "Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia". The primary purpose of this study was to assess the effect of aspirin (ASA) on niacin extended-release (NER)-induced flushing in subjects with dyslipidemia.
What is the current status of trial NCT00626392?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 277 participants. The study started on 2008-02. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00626392?
The interventions under investigation include: aspirin (ASA) (DRUG), niacin extended-release (NER) (DRUG), aspirin placebo (ASA Pbo) (DRUG).
Who is sponsoring clinical trial NCT00626392?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.